nabu.science
MethodologyAboutContact

 

  • Snapshot
  • Key Claims
  • Strengths & Limitations
  • Commentary
  • From the Authors
  • Author Note / Field Feedback
  • Dimension breakdown
  • Impact Profile
Free · About 5 minutes
Report #NBU-5CB3C2F9·Framework v5.9·Pipeline v0.4·Evaluated 08 Oct 2026·OECD: 3.2 Clinical medicine·Subfield: Neurology·Basis: Full text·Type: Laboratory experiment

Mechanisms of increased Alzheimer's disease pathology with R47H and R62H TREM2 variants.

Fancy et al.Fancy, Willumsen, Chau et al.·2026·Acta neuropathologica·10.1007/s00401-026-03036-z ↗

Primary claim

Epistasis between CD33 and TREM2 was demonstrated by relative normalisation of differences in β-amyloid load in TREM2var carriers of the protective CD33 allele.

Tentative · small stratified groups and no reported formal interaction test limit the observational epistasis inference
In brief

A valuable multimodal human TREM2 resource generates genotype-specific hypotheses, but small, inconsistently reported strata cannot establish the claimed epistasis or mechanisms.

ReliabilityCaveats4 of 4 checks completeRead the 2 entries ↓
Unlikely to hold — the claim's weakest requirement is that the effect exists at all. Experimental. Every point below is traceable to a quoted passage, but this forecast has not yet been validated against known replication outcomes.
Abstract

TREM2 plays multiple functional roles in microglia and variants are associated with increased risks of Alzheimer's disease (AD). Genetic polymorphisms reducing expression of the functionally related protein CD33 are protective. Here we have contrasted cellular pathology in human post-mortem brain with and without AD to test mechanisms associated with the differential genetic risks conferred by R47H and R62H TREM2 variants (TREM2var) with and without heterozygosity for the protective rs3865444 CD33 polymorphism. Epistasis between CD33 and TREM2 was demonstrated by relative normalisation of differences in β-amyloid load in TREM2var carriers of the protective CD33 allele. These functional differences were mirrored by differential microglial transcriptomic responses to β-amyloid. Controlling for CD33 genotype, microglial transcriptional responses to increasing β-amyloid were lower for TREM2var, particularly for R47H compared to CV, and there was a reduction in expression of neuroplasticity pathways in TREM2var. R62H microglial signatures were distinguished from those of R47H by upregulation of genes associated with phagocytosis and from CV by differences in inflammatory gene expression including those involved in NF-kappaB signalling. Differential gene expression with increasing β-amyloid also suggested upregulation of β-amyloid production and binding pathways in excitatory neurons in TREM2var heterozygotes. There was lower enrichment for pathways positively adaptive to pathology and expressed in inhibitory neurons from CV samples for both TREM2var. Exploratory bulk tissue proteomics support these observations with evidence for adaptive plasticity in response to β-amyloid pathology in CV tissue not found for the TREM2var, which showed evidence of increased β-amyloid formation and neuroplasticity changes. Together, these results highlight differences in molecular pathology between CV and TREM2var and between the TREM2var risk variants. They highlight mechanisms of AD risk mediated by secondary effects on astroglial and neuronal functions. Demonstration of strong epistasis between TREM2 and CD33 with AD supports the therapeutic potential of modulators of CD33 inhibition or expression.

Key Claims

Primary finding · Tentative

Epistasis between CD33 and TREM2 was demonstrated by relative normalisation of differences in β-amyloid load in TREM2var carriers of the protective CD33 allele.

Unlikely to hold — the claim's weakest requirement is that the effect exists at all. Experimental. Every point below is traceable to a quoted passage, but this forecast has not yet been validated against known replication outcomes.

small stratified groups and no reported formal interaction test limit the observational epistasis inference

Abstract; Results, Figure 1c
Quote verified
Secondary · Tentative

Controlling for CD33 genotype, microglial transcriptional responses to increasing β-amyloid were lower for TREM2var, particularly for R47H compared to CV.

unequal sample sizes, low R47H power, and unclear CV accounting confound DEG-count comparisons

Abstract; Results, Differential transcriptomic responses; Figure 3b
Quote verified
Secondary · Tentative

Differential gene expression with increasing β-amyloid also suggested upregulation of β-amyloid production and binding pathways in excitatory neurons in TREM2var heterozygotes.

pathway associations are appropriately hedged but derive from small, unequal observational genotype groups

Abstract; Results, Figure 5
Quote verified
Secondary · Tentative

They highlight mechanisms of AD risk mediated by secondary effects on astroglial and neuronal functions.

cross-sectional post-mortem expression associations cannot identify causal mediation of disease risk

Abstract; Discussion, paragraphs 5–7
Quote verified

Derived from the full evaluation — not a separate score.

Strengths · Limitations

Strengths

#contribution

Rare multimodal human variant cohort

The study integrates IHC, imaging mass cytometry, snRNA-seq, and proteomics across R47H, R62H, and common TREM2 genotypes. This provides a useful human-tissue resource for comparing rare risk variants.

↳ Methods; Results, Figures 1–5

#methodological rigour

Donor-aware transcriptomic modelling strategy

Nuclei are aggregated into donor-specific pseudocells, and donor identity is included as a random effect alongside pathology, genotype, region, sex, APOE4, CD33, and technical covariates.

↳ Methods, Differential gene expression analysis

#positioning

Substantive discussion of study limits

The Discussion addresses rare-variant scarcity, subgroup imbalance, snRNA-seq sparsity, post-mortem artefacts, contralateral pathology measurement, and absent spatial or molecular plaque characterization.

↳ Discussion, limitations paragraph

Limitations

#methodological rigour

Transcriptomic sample accounting is inconsistent

The Methods call the CV snRNA-seq set 48 blocks but list 18 NDC and 21 AD blocks, while the regional AD counts sum to 30. This uncertainty bears directly on central genotype-specific transcriptomic comparisons.

↳ Methods, Single nucleus isolation for single nuclear RNA sequencing

#reporting

Epistasis claim exceeds reported analysis

The paper calls epistasis demonstrated and strong, although the key R47H result comes from small CD33-stratified groups, Figure 1e reports trends, and no formal TREM2-by-CD33 interaction test is reported.

↳ Abstract; Results, Figure 1c and 1e; Discussion, final paragraph

#positioning

Power limitation is interpreted backwards

Only 34.8% of equivalent CV-associated effects were estimated detectable at the R47H sample size, yet the Discussion treats the reduced DEG count as genuine biological dampening. Low detectability cannot distinguish dampening from underpowering.

↳ Discussion, paragraph beginning “Functional changes with TREM2 KO”

Does this match your read? Add your assessment ↓

Nabu Commentary

The principal value lies in combining pathology, cell-type transcriptomics, and proteomics across two rare TREM2 variants in human cortex. The donor-aware pseudocell model is appropriate for repeated nuclei, but the rare genotype-by-CD33 groups are very small and the reported CV block count is internally inconsistent. Figure 1 supports an R47H-associated CD33-stratified amyloid difference, not a definitive interaction across variants, while the transcriptomic comparisons are strongly affected by unequal power. The final mechanistic and therapeutic framing therefore exceeds what cross-sectional post-mortem associations can establish.

Evaluate another paper

Free · About 5 minutes · Research preview

Author Note / Field Feedback

Nabu’s assessment, alongside the field’s view.

Are you an author of this paper?

Dimension breakdown

Evidence Score

Out of 5
012345
2.9±0.2

Contribution
3.5

The study meaningfully extends TREM2 research into multimodal human post-mortem tissue, comparing R47H, R62H, and common variants across pathology and cell-type expression. Its advance is constrained because the proposed human CD33–TREM2 interaction remains exploratory rather than demonstrated.

Introduction; Results, Figures 1–5; Discussion, paragraphs 1–2

“Epistasis between CD33 and TREM2 was demonstrated”

Methodological Rigour
2.6

The pseudocell analysis models donor dependence and includes relevant genotype and technical covariates, but rare-variant strata are small and important age, PMI, and RIN imbalances remain. Cross-sectional associations are interpreted mechanistically, and the central CV snRNA-seq sample accounting is inconsistent.

Methods, Differential gene expression analysis; Methods, Single nucleus isolation; Table 1; Discussion

“Donor identity was included as a random effect”

Reporting
3.2

The progression from histology through cell-type transcriptomics and proteomics is readily followable. However, headline terms such as “demonstrated,” “strong epistasis,” and “genuine biological dampening” communicate greater certainty than the interaction and power evidence warrants.

Abstract; Discussion, paragraphs 3 and final

“The attenuated response in R47H therefore reflects a genuine biological dampening”

Positioning
2.8

The paper engages relevant mouse, in-vitro, human-tissue, and therapeutic literature and gives a substantive limitations discussion. Contextual honesty is reduced because acknowledged scarcity, imbalance, and low detectability are followed by strong biological conclusions that those limitations undercut.

Introduction; Discussion, limitations paragraph and final paragraph

“34.8% of CV-associated genes would be detectable at 0.8 power”

Reliability

Caveats4 of 4 checks


Results checkNoted
  • Controlling for CD33 genotype, microglial transcriptional responses to increasing β-amyloid were lower for TREM2var, particularly for R47H compared to CV: "CV (48 total: n = 18, NDC [9 MTG, 9 SOM]; n = 21, AD" (Methods, Single nucleus isolation for single nuclear RNA sequencing) vs "AD [19 MTG, 11 SOM]" (Methods, Single nucleus isolation for single nuclear RNA sequencing). The stated disease subtotals give 18 + 21 = 39 CV blocks, whereas the AD regional counts give 19 + 11 = 30 and hence 18 + 30 = the stated 48 CV blocks; this accounting correction does not change a reported expression result. → Conclusion holds
Reporting and transparencyNoted

The Figure 1 legend labels the donor count as tissue blocks, and the methods name a paired Wilcoxon test for genotype-group comparisons without establishing the pairing or the test actually run.

Conflict of interest: not stated · Ethics approval: declared · Data availability: declared · Code availability: not stated

Reference IntegrityClean

75 references in manuscript 74 of 74 checkable references found in an index 1 are books, websites or datasets — counted, but not index-checkable

References not verified automatically are resolved manually within 24 hours.

Post-Publication RecordClean

No retraction or expression of concern found in Crossref (includes Retraction Watch).

Last checked: 17 Oct 2026

Sources: Crossref (incl. Retraction Watch) ✓

Impact Profile

Impact areaHealth · Neurological · Alzheimer's disease and other dementias
Type of advanceEmpirical
Route to useSpecified
AdvanceExtends
BeneficiariesLarge
CitationsToo early
Policy · patentNot yet traced
ReachedNot reachedNot assessable or unverified
ReadinessFoundational
Foundational
Controlled
Piloted
Validated
Implementable
FoundationalImplementable

The epistasis claim rests on observational post-mortem human tissue analyses with no intervention or controlled experiment shown working.

From the paper
“demonstration of strong epistasis between TREM2 and CD33 with AD should be considered in TREM2 agonist trials”

The paper names the setting (TREM2 agonist trials) and how the findings should be applied there, plus therapeutic use of CD33 expression modulators.

Pathway

Drug developers designing TREM2 agonist or CD33-modulating therapies would stratify trial populations by CD33 genotype and target CD33 inhibition.

Barrier

The finding is correlative in rare post-mortem tissue, and therapeutic CD33 modulation must still be shown to work in living patients.

Evaluated 13 Nov 2026 · GBD 2023 · glm_v1_3_3 · impact_profile_v1_3_3

Report an issue →

AI-generated, human-governed. Something look off? Contact us to request a review.

Keep reading

Related evaluations

Other papers Nabu has evaluated blind, starting with the same field.

  1. Early Regional Microglial Remodelling in the Hippocampus of the AppAlzheimer's Model

    2026 · Basic medicine

    Primary claim

    These findings demonstrate that hippocampal microglia in App NL‐G‐F mice undergo an early, coordinated structural remodelling before local amyloid deposition becomes apparent.

    Tentative
    Evidence Score
    3.5±0.2
    Reliability
    No concerns
  2. Using iPSC models to examine neuron-glia interactions in neurodegenerative diseases

    Lopez, Keavey, Bowles · 2026 · Basic medicine

    Primary claim

    current work utilising co-culture and 3D iPSC models reveals that neuron–glial interactions in AD, PD, and primary tauopathies underlie a progressive, toxic bi-directional feed-forward cycle

    Tentative
    Evidence Score
    3.1±0.2
    Reliability
    No concerns
  3. Multiscale Approximations to Understand the Complex Role of Microglia in Alzheimer's Disease

    Martínez-Tazo, Mejias-Ortega, López-López, et al. · 2026 · Basic medicine

    Primary claim

    Microglia play a multifaceted and stage-dependent role in Aβ plaque biology, acting not only as phagocytes but also as structural regulators of plaque architecture.

    Supported
    Evidence Score
    3.2±0.2
    Reliability
    Caveats

How the rubric works →